Victoria Socha

DocwireNews

Autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease, accounts for 10% of causes of end-stage renal disease. In 2014, tolvaptan was approved as the first targeted therapy for ADPKD. However, there are few reported data on the real-world experiences of patients with ADPKD treated with tolvaptan. Judith Fatima Martins Munoz, MD, PhD, and colleagues in Spain conducted a study designed to characterize the effectiveness and safety profile of patients during the first 2 years of treatment with tolvaptan.Results of the retrospective observational study were reported during a poster session at Kidney Week 2019. The poster was titled Two Years of Follow-Up Experience with Tolvaptan Treatment in Autosomal Dominant Polycystic Kidney Disease.The study cohort included 143 patients with ADPKD with chronic kidney disease stage (CKD) 1 to 4 who were treated with tolvaptan. Baseline data were collected from 15 centers in Madrid, Spain; the data included laboratory values and kidney volume.Mean follow-up was 8.7 months, 51% of the participants were women, mean age was 42.7 years, mean baseline estimated glomerular filtration rate was 63 mL/min/1.73 m2, and mean urine osmolality was 445 mOsm/kg. At baseline, 19.6% of participants had stage 1 CKD, 34.3% had stage 2, 27.3% had stage 3a, 16.8% had stage 3b, and 2.1% had stage 4. Total kidney volume was 1695; class of Mayo Clinic classification was: 1B, 0.7%; 1C, 23.8%; 1D, 31.5%; and 1E, 24.5%. Median dose achieved was 100.69 mg in 4.9 weeks.The rate of adverse events was 74.1%; 68.6% of those were related to increased aquaresis (thirst, polyuria, nocturia, and polydipsia). Liver-enzyme levels were elevated in 14 cases; there were no reported cases of severe liver injury.After 10.9 months, 31 patients (21.6%) discontinued treatment. The primary reasons for discontinuation were aquaretic effects (86%), elevation of liver-enzyme level (7%), and other (3.5%). Nine patients of the 31 who discontinued reinitiated treatment after a median of 7.02 months. The overall adherence rate was 84.6%. Renal function at 1, 6, 12, 18, and 24 months was 59.83 mL/min/1.73 m2; 56.58 mL/min/1.73 m2, 58.38 mL/min/1.73 m2, 60.21 mL/min/1.73 m2, and 62.87 mL/min/1.73 m2, respectively.In conclusion, the authors said, &ldquo;In our experience tolvaptan could be considered as a safe drug in patients with ADPKD. The adherence of the treatment was good, with similar data obtained in TEMPO 3:4 trial. Due to adverse events, it is necessary to monitor the enzyme liver levels, but no cases of fatal liver damage were reported. The renal function remained stable after two years of treatment.&rdquo;Source: Martins Munoz JF, Gutierrez-Martinez E, Ortiz A. Two years of follow-up experience with tolvaptan treatment in autosomal dominant polycystic kidney disease. Abstract of a poster presented at the American Society of Nephrology Kidney Week 2019 (Abstract TH-PO841), November 7, 2019, Washington, DC.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Tolvaptan for ADPKD: Two-Years of Follow-up

National Kidney Foundation 2020

Autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease, accounts for 10% of causes of end-stage renal disease. In 2014, tolvaptan was ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe